Nuvectis Pharma Inc. (NVCT)
NASDAQ: NVCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $666.80M
- EPS (TTM)
- -$2.00
- Dividend yield
- None
- 52-week range
- 5.77 – 29.28
- Day range
- 19.02 – 20.18
- Volume / Avg
- 301.60K / 206.37K
- Beta
- —
- Shares outstanding
- 34.39M
52-week range
NVCT stock today
On Nov 20, NVCT ended the session at $19.39, shedding $0.45 (2.27%), versus the S&P 500's 3.70% decline. Shares are 33.8% below their 52-week high of $29.28, set on Jun 29, 2026 and 236.0% above the 52-week low of $5.77, in the middle of the past year's range. NVCT is up 156.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 218.9%.
Nuvectis Pharma has posted a net loss over the last twelve months (EPS of -$2.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nuvectis Pharma
Company profileNuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ron Bentsur M.B.A.
- Headquarters
- Fort Lee, NJ
- Employees
- 19
- IPO year
- 2022
- Website
- nuvectis.com
Financial highlights
Full financialsNuvectis Pharma reported a net loss of $26.4 million, compared with a loss of $19.0 million a year earlier. Diluted earnings per share came in at -$1.32.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-26.44M | $-19.00M | $-22.26M | $-19.09M | $-12.89M |
| EPS (diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$35.40+82.57%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.44 vs $-0.22
- Surprise
- -100.00%
NVCT news
All NVCT news- Nuvectis Pharma, Inc. Reports Third Quarter 2026 Financial Results and Business HighlightsNasdaq
- Nuvectis (NVCT) Q3 2026 Earnings Call TranscriptNasdaqNVCT, BF.A
- Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswire
- Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire
- Nuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent GliomasNasdaqNVCT, LEN.B
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026GlobeNewswire
Nuvectis Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs NVCT |
| LXRXLexicon Pharmaceuticals Inc. | 1.53 | -8.38% | $681.21M | vs NVCT |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs NVCT |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs NVCT |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs NVCT |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs NVCT |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs NVCT |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs NVCT |
Indexes, lists and sector
Nuvectis Pharma stock FAQ
What is Nuvectis Pharma's stock price today?
NVCT last traded at $19.39 as of Nov 20, 4:00 PM EST, down 2.27% on the day. Prices are delayed at least 15 minutes.
Who is Nuvectis Pharma's CEO?
Mr. Ron Bentsur M.B.A. is the chief executive officer of Nuvectis Pharma Inc., which has about 19 employees.
What is the NVCT 52-week high?
The 52-week high for NVCT is $29.28 and the 52-week low is $5.77. The stock is currently 33.8% below its high.